Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy
Abstract Purpose Cisplatin is a critical component of first‐line chemotherapy for several cancers, but causes peripheral sensory neuropathy, hearing loss, and tinnitus. We aimed to identify comorbidities for cisplatin‐induced neurotoxicities among large numbers of similarly treated patients without...
Main Authors: | Xindi Zhang, Matthew R. Trendowski, Emma Wilkinson, Mohammad Shahbazi, Paul C. Dinh, Megan M. Shuey, Regeneron Genetics Center, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Chunkit Fung, Christian Kollmannsberger, Robert Huddart, Neil E. Martin, Victoria A. Sanchez, Robert D. Frisina, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis, M. Eileen Dolan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-07-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.4644 |
Similar Items
-
Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer
by: Mohammad Shahbazi, et al.
Published: (2023-02-01) -
Association of hearing loss and tinnitus symptoms with health‐related quality of life among long‐term oropharyngeal cancer survivors
by: Puja Aggarwal, et al.
Published: (2023-01-01) -
Development of Tinnitus and Hyperacusis in a Mouse Model of Tobramycin Cochleotoxicity
by: Ryan J. Longenecker, et al.
Published: (2021-09-01) -
Comparison of GWAS results between de novo tinnitus and cancer treatment-related tinnitus suggests distinctive roles for genetic risk factors
by: Mohammad Shahbazi, et al.
Published: (2024-11-01) -
Topical gentamicin-induced acute vestibulopathy: A case report
by: Teik Beng Lau, et al.
Published: (2023-05-01)